Regd. Unit No 101, 1st Floor, KCD Jogesh Eva, Road No.1, Jogeshwari (East), Mumbai - 400 060

Phone: 9137322030 Email: compliance@kcdindustries.com Web: www.kcdindustries.com Extracts of the Statement of Un-audited Financial Results for the Quarter Ended 30th June 2024 (Rs. in Lacs except EPS Standalone Quarter Ended on Consolidated Quarter Ended on **Particulars** 30.06.2024 30.06.2023 30.06.2024 30.06.2023 Un-audited Un-audited Un-audited Un-audited Total income from operations (net) 660.857 851.055 660.857 851.055 Net Profit/(Loss)for a period (before tax, Exceptional and/or 19.329 19.329 65.374 65.374 Extraordinary items) Net Profit/(Loss)for a period before tax (after Exceptional and/or 19.329 65.374 Extraordinary items) 19.329 65.374 Net Profit / (Loss) for the period after tax (after Exceptional and/or 65.374 13.299 65.374 Extraordinary items) 13.299 Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income 13.299 13.299 65.374 65.374 Equity Share Capital 371.429 100 371.429 100 Earnings Per Share (of Rs.1 each) (for continuing and discontinued operations) -

The above result is an extract of the detailed format of Un-audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2024 filed with Stock Exchange under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the guarterly results is available on website of Stock

 Basic: 2. Diluted:

Note:

Figures of the previous year have been re-grouped/ re-arranged / re-classified wherever considered necessary. For KCD Industries India Limited

Rajiv Darji Place:Mumbai Managing Director DIN: 02088219 Date: 12th August 2024

POST OFFER ADVERTISEMENT UNDER REGULATION 18 (12) OF SECURITIES AND **EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES** AND TAKEOVERS) REGULATIONS, 2011, AND AMENDMENTS THERETO FOR THE ATTENTION OF THE PUBLIC SHAREHOLDERS OF

0.047

0.047

0.654

0.654

0.047

0.047

0.654

0.654

FOODS AND INNS LIMITED CIN: L55200MH1967PLC013837

Registered Office: Udyog Bhavan, 2nd Floor 29 Walchand Hirachand Marg, Ballard Estate, Mumbai City, Mumbai, Maharashtra, India-400038. Corporate Office: J. N. Heredia Marg, Hamilton House, 3rd floor, Ballard Estate, Mumbai, Maharashtra, India, 400038 Contact No.: +91 22 2261 3102 Email ID: cs@foodsandinns.com. Website: https://www.foodsandinns.com/

Open Offer for acquisition of up to 1,90,79,617 fully paid-up equity shares of face value of ₹1 each representing 26.00% of the Expanded Voting Share Capital of Foods and Inns Limited ("Target Company") at a price of ₹147 per equity share from the public shareholders of the Target Company by Raymond Simkins ("Acquirer 1") and Milan Bhupendra Dalal ("Acquirer 2") (hereinafter Acquirer 1 and Acquirer 2 are collectively referred to as "Acquirers"), along with Borgos Multitrade LLP (deemed to be Person Acting In Concert with Acquirer 2 or "PAC", for the purpose of the Open Offer) pursuant to and in compliance with Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto ("SEBI (SAST) Regulations, 2011") ("Open Offer" or "Offer").

This post-offer advertisement ("Post-Offer Advertisement") is issued by Inga Ventures Private Limited and Pioneer Investcorp Limited ("Managers to the Open Offer"), in respect of the Open Offer, for and on behalf of the Acquirers along with the PAC to the Public Shareholders of the Target Company, pursuant to and in compliance with Regulation 18 (12) of SEBI (SAST) Regulations, 2011. The detailed public statement dated April 16, 2024 ("Detailed Public Statement" or "DPS") with respect to the aforementioned Offer was published on April 18, 2024 in the following newspapers:

Newspaper	Language	Edition(s)		
Financial Express	English	All Editions		
Jansatta	Hindi	All Editions		
Pratahkal	Marathi	Marathi Edition		

The Shareholders of the Target Company are requested to kindly note the following information with respect to the Open Offer:

1)	Name of the Target Company	:	Foods and Inns Limited						
2)	ame of the Acquirer(s) and PAC : 1) Raymond Simkins				Acquirer 1				
			2) Milan Bhupendra Dalal : Ac						
			Borgos Multitrade LLP	:	PAC				
3)	Name of the Manager to the Offer		Inga Ventures Private Limited						
100			Pioneer Investcorp Limited						
4)	Name of the Registrar to the Offer	:	Link Intime India Private Limited						
5)	Offer Details: a) Date of Opening of the Offer b) Date of Closure of the Offer	2002	Tuesday, July 23, 2024 Monday, August 05, 2024						
6)	Date of Completion of Payment of Consideration and communication of Rejection/Acceptance		Friday, August 09, 2024						

Details of Acquisition:

Sr. No.	Particulars	HIS ALIED SHIPS TO LOCK TO A THE STREET AND	the Letter of	Actuals ⁽¹⁾		
7.1	Offer Price (in ₹)	₹147 per Equity Share		₹147 per	Equity Share	
7.2	Aggregate number of Shares tendered		Up to 1,90,79,617 ⁽²⁾	5,00,7		
7.3	Aggregate number of Shares accepted		Up to 1,90,79,617 ⁽²⁾	5,00,7		
7.4	Size of the Offer (Number of Equity Shares multiplied by Offer Price per Equity Share)	₹2	80,47,03,699(3)	₹7	7,36,04,664(3)	
7.5	Shareholding of the Acquirers before Public Announcement Number More Share Capital		81,28,910 11.08%		81,28,910 11.08%	
7.6	Shares acquired by way of Agreement / Preferential Allotment Number More Share Capital	Nil			Nii	
7.7	Shares Acquired by way of Open Offer Number Share Capital		1,90,79,617 26%	5,00,712 ¹⁴ 0.68%		
7.8	Shares acquired after Detailed Public Statement ("DPS") Number More Share Capital Price of the Shares acquired		Nil	N		
7.9	Post Offer Shareholding of the Acquirers Number Share Capital		81,28,910 86 11.08%		86,29,622 11.76%	
7.10	[[장] [전] 이 이 이 이 집에 가는 사람이 되었다. [[] 하는 사람이 있는 사람이 하는 사람이 있다. 그 사람이 있다는 사람이 없는 사람이 없다.	Pre-Offer	Post Offer	Pre-Offer	Post Offer	
	Public (other than Acquirers and PAC): Number More Spanded Voting Share Capital	5,48,83,422 74.79%	3,58,03,805 ⁽²⁾ 48.79% ⁽¹⁾		The second of th	

- Assuming full acceptance in the Open Offer. Excludes Brokerage and other charges.
- All the Equity Shares tendered and acquired in the Offer were in dematerialized form and none were in physical form.
- The Acquirers, the PAC and its designated Partners accept full responsibility for the information contained in this Post Offer Advertisement and also for the obligations under SEBI (SAST) Regulations, 2011.
- A copy of this Post Offer Advertisement will be available on the websites of SEBI (www.sebi.gov.in), BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and will be dispatched to the registered office of the Target Company.

Capitalized terms used in this Post-Offer Advertisement, but not defined herein, shall have the same meanings assigned to such terms in the Letter of Offer dated July 10, 2024.

Issued by Managers to the Offer on behalf of the Acquirers and the PAC:



Inga Ventures Private Limited

1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai, 400 069, Maharashtra, India Tel. No.: +91 22 68510808

Contact Person: Kavita Shah E-Mail: foodsandinns.oo@ingaventures.com SEBI Regn No.: INM000012698



Pioneer Investcorp Limited 1218, 12th Floor, Maker Chambers V, Nariman Point, Mumbai, 400021 Tel. No.: +91 22 66186633:

Contact Person: Varun Jain E-Mail: projectfood@pinc.co.in SEBI Regn No.: INM000002988

For and on behalf of the Acquirers and PAC

Place : Mumbai

("Acquirer 2") Date: August 14, 2024

Milan Bhupendra Dalal

FINANCIAL EXPRESS

Sr.

Particulars

WWW.FINANCIALEXPRESS.COM

glenmark

GLENMARK PHARMACEUTICALS LIMITED

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099. Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986; Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com; CIN: L24299MH1977PLC019982

Standalone

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026;

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Consolidated

THURSDAY, AUGUST 15, 2024

Sr.	Particulars	Standalone			Consolidated				
No.	50.000.000.00	Quarter ended	Quarter ended	Quarter ended	Year ended	Quarter ended	Quarter ended	Quarter ended	Year ended
		30/06/2024 (Unaudited)	31/03/2024 (Refer note 7)	30/06/2023 (Unaudited)	31/03/2024 (Audited)	30/06/2024 (Unaudited)	31/03/2024 (Refer note 7)	30/06/2023 (Unaudited)	31/03/2024 (Audited)
T	Revenue from operations	(Unaddited)	(Kelei liote /)	(Onaudited)	(Auditeu)	(onauditeu)	(Neier flote /)	(Ollaudited)	(Audited)
	(a) Net sales	22,968.75	20,771.32	20,980.62	76,497,61	32,233.02	30,160.07	29,984.72	1,16,354.56
	(b) Other operating income	326.62	710.91	463.22	2,413.58	208.84	469.45	375.94	1,776.41
II	Total revenue from operations Other income	23,295.37 556.48	21,482.23 7,862.70	21,443.84 493.61	78,911.19 11,680.24	32,441.86 314.92	30,629.52 7,731.65	30,360.66 197.22	1,18,130.97 8,399.94
101	Total income (I + II)	23,851.85	29,344.93	21,937.45	90,591.43	32,756.78	38,361.17	30,557.88	1,26,530.91
IV	Expenses		3/	8		16		50	55/65
	(a) Cost of materials consumed (b) Purchases of stock-in-trade	6,481.09 889.85	6,854.51 816.58	7,967,56 821,71	29,904.11 3,227.82	6,857.74 3,600.26	7,543,09 2,108.04	8,302.54 4,184.25	31,578.22 14,511.70
	Purchases of stock-in-trade Changes in inventories of finished goods, work-in-progress	569.24	(21.20)	(230.84)	(1,030.70)	642.82	304.15	(608.82)	(1,956.22)
	and stock-in-trade		1003-09-950	estrevenese A:	U. 2004-000-001-001-0	SYMPONIO	20000000	***********	O settle settle settle
	(d) Employee benefits expense (e) Finance costs	3,844.03 153.49	3,377.45 833.85	3,344.66 619.34	14,347.75 2,771.10	7,104.40 395.82	7,009.55 1,485.59	6,812.73 1,116.08	28,681,43 5,159,69
	(e) Finance costs (f) Depreciation, amortisation and impairment expense	530.87	524.01	487.52	2,021.62	1,177.89	1,513.37	1,420.40	5,819.06
	(g) Other expenses	5,200,14	5,480.41	4,690.79	20,045.58	8,354.51	8,621.26	7,296,44	33,362.53
	Total expenses (IV)	17,668.71	17,865.61	17,700.74	71,287.28	28,133.44	28,585.05	28,523.62	1,17,156.41
V	Profit/(loss) before exceptional items and tax (III - IV) Exceptional items (gain)/ loss (Refer note 5)	6,183.14	11,479,32 (51,469.13)	4,236.71 316.29	19,304.15 (50,703.31)	4,623.34	9,776.12 4,467.85	2,034.26 520.23	9,374.50 9,009.55
VII	Profit/(loss) before tax from continuing operations	6,183.14	62,948.45	3,920.42	70,007.46	4,623.34	5,308.28	1,514.03	364.95
00000	(V - VI)	200000000000000000000000000000000000000	ASTRIBATION.	33333333	(10000000000000000000000000000000000000	212222	17.68.77(777)	MTGMGTEN.	550,000
VIII	Tax expense:	24.070.04	40.550.70	205.05	10.100.00	4 400 00	40 504 74	: pay 200:	44 455 50
	Current tax Deferred tax	1,079.84 565.99	10,553.79 6,257.71	385.65 818.21	10,499.92 7,834.63	1,468.82 (247.86)	10,581.74 7,112.99	567.23 570.02	11,155,52 7,517.93
IX	Profit/(loss) after tax for the period from continuing operations	4,537.31	46,136.95	2,716.56	51,672.91	3,402.38	(12,386.45)	376.78	(18,308.50)
336	(VII - VIII)		E-9000038-63	Storestinent	9000700007,4401.1	08000800-000	2000/2018/24/2019	50000000	O78056633308.5A
Х	Profit/(loss) for the period from continuing operations attributable to: - Non-controlling interests				60	(0.29)	40.10	231.94	681,46
	- Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	(12,426.55)	144.84	(18,989.96)
XI.	Profit/(loss) before tax from discontinued operations	NAME AND ASSOCIATION OF THE PARTY OF THE PAR	10071007100	3037/-03827575	10000000000000000000000000000000000000	- Altrana	310.80	1,820.04	5,326,92
XII	Tax expense of discontinued operations :						2000000	101/01/01/01/01	1611 DOMESTIC
	Current tax Deferred tax						72.73 (5.69)	435,99 29.55	1,284.32 69.32
XIII	Profit/(loss) after tax for the period from discontinued operations					2	243.76	1,354.50	3,973.28
500000	(XI - XII)						(70000000)	15000000000	0.000.0000
XIV	Profit/(loss) for the period from discontinued operations attributable to: Non-controlling interests					20	82		
	- Owners of the Company					8.	243.76	1,354.50	3,973.28
XV	Profit/(loss) after tax for the period from continuing and discontinued					3,402.38	(12,142.69)	1,731.28	(14,335.22)
XVI	operations (IX + XIII) Profit/(loss) for the period from continuing and discontinued								
OV!	operations attributable to:								
	- Non-controlling interests	47		-	51	(0.29)	40.10	231.94	681.46
V/C/III	- Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	(12,182.79)	1,499.34	(15,016.68)
XVII	Other comprehensive income from continuing operations A (i) Items that will not be reclassified to profit or loss	(12.52)	(9.74)	(7.50)	(73.14)	(7.01)	(94.10)	(5.52)	(163.06)
	(ii) Income tax relating to items that will not be reclassified to	4.37	9.44	2.23	25.56	2.79	26.65	2.23	42,75
	profit or loss					20.50	040.57	/F04 07	(000.00)
	B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit	(4			*	60.50 (1.36)	846.57 (20.13)	(564.37) 6.80	(399.03) (79.97)
	or loss		S		51	(1.50)	(20,10)	9.00	(10.01)
(VIII	Total comprehensive income from continuing operations for the	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,627.47)	(184.08)	(18,907.81)
XIX	period/ year Other comprehensive income from discontinued operations for the						(0.19)	(0.73)	(56.23)
	period/ year						(0.19)	(0.73)	(00.20)
XX	Total comprehensive income from discontinued operations for the					25	243.57	1,353.77	3,917,05
XXI	period/ year (XIII + XIX) Other comprehensive income for the period/ year from continuing	(8.15)	(0.30)	(5.27)	(47.58)	54.92	758.79	(561.59)	(655.53)
neni:	and discontinued operation (XVII + XIX)	(0.10)	(0.50)	(0.21)	(47.50)	34.52	130.73	(001.03)	(00,00)
XXII	Total comprehensive income for the period/ year from continuing	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,383.89)	1,169.69	(14,990.76)
XXIII	and discontinued operation (XVIII + XX) Total comprehensive income attributable to:						50.00		
AAJII	Non-controlling interests					(0.26)	40.22	231.98	672.00
0628950	- Owners of the Company	4,529.16	46,136.65	2,711.29	51,625.33	3,457.56	(11,424.11)	937.71	(15,662.76)
VIX	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282,19
XXV	Other equity (other than revaluation reserve) Earning per share for continuing operations (EPS)				2,29,424.01				78,197.08
SS.VII.	(not annualised except for the year ended 31 March)								
	Basic (in Rupees)					12.06	(44.04)	0.51	(67,30)
200 M	Diluted (in Rupees)					12.06	(44,04)	0.51	(67,30)
OCVIII	Earning per share for discontinued operations (EPS) (not annualised except for the year ended 31 March)								
	Basic (in Rupees)					72	0.86	4.80	14.08
6000000	Diluted (in Rupees)						0.86	4.80	14.08
XVIII	Earning per share for continuing and discontinued operations (EPS)								
	(not annualised except for the year ended 31 March) Basic (in Rupees)	16.08	163.50	9.63	183.13	12.06	(43.17)	5.31	(53.22)
	Diluted (in Rupees)	16.08	163.50	9.63	183.12	12.06		5.31	(53.22)

Diluted (in Rupees) Notes:

- 1. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2. The above results were reviewed by the Audit Committee at its meeting held on 13th August, 2024 and approved by the Board of Directors at their meetings held on 14th August, 2024. The results for the quarter ended 30" June, 2024 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- 3. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- 4. As at 30th June, 2024, pursuant to Employee Stock Options Scheme 2016, 37,779 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

A. On 6 March , 2024, 6,73,89,944 equity shares, representing 55% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer.

Exceptional items:

Standalone:

Pursuant to Board approval dated 21 September 2023, the Company entered into share purchase agreement with Nirma Limited (the "Buyer") for the sale of 91,895,379 equity shares representing 75.00% of the current issued and paidup equity share capital of Glenmark Life Sciences Limited ("GLS"), a subsidiary of the Company, to the Buyer at a price of INR 615/- per share, aggregating to INR 56,515 million (subject to adjustments as agreed among the parties), in accordance with the terms of the share purchase agreement dated 21 September 2023 among the Company, GLS and the Buyer. Accordingly, 91,895,379 equity shares representing 75% of the current issued and paid-up equity share capital of the GLS, were transferred by the Company to Buyer as follows:

Exceptional item in the standalone result for the quarter and year ended 31 March 2024 Rs. 51,469.13 million (gain) and Rs 50,703.31 million (gain) respectively, primarily comprises of stake sale (net of expenses)

B. On 12 March , 2024, 2,45,05,435 equity shares, representing 20% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer.

As required by Ind-AS 105 "Asset Held for Sale and Discontinued Operations," GLS had been classified as discontinued operations after eliminating intercompany transactions and relevant disclosures made in the financial results. 30.06.2023

Exceptional item of Rs.316.29 in the standalone result for the quarter comprises of remediation cost of manufacturing sites in India.

Consolidated:

31.03.2024

Exceptional item in the Consolidated result for the quarter and full year ended 31 March 2024 is Rs. 4,467.85 million (loss) and Rs 9,009.55 million (loss) respectively primarily comprises of stake sale (net of expenses) in Glenmark Lifescience Ltd, impairment of certain block at Monroe facility, De-prioritisation of certain intangibles, settlement & legal cost, remediation cost and working capital adjustments. The US subsidiary Glenmark Pharmaceuticals Inc., USA ('Company') has entered into an agreement with the U.S. Department of Justice, Antitrust Division (DOJ) on 22 August , 2023 to resolve all of its court

proceedings with the DOJ involving historical pricing practices relating to the generic drug pravastatin between 2013 and 2015. The Company has entered into a three-year Deferred Prosecution Agreement, and if the Company adheres to the terms of the agreement, including the payment of \$30 million, payable in six instalments, the DOJ will dismiss the pending Superseding Indictment. The US subsidiary Glenmark Pharmaceuticals Inc., USA ('Company') is likely to enter into an agreement with the U.S. Department of Justice, Antitrust Civil Division (DOJ), subject to all necessary approvals being in place, to the extent of \$30 million (including related cost), to resolve all of its Civil court proceedings with the DOJ. Due to the non-recurring nature of the provision, the Company has classified this provision as an

exceptional item in the financial statements for the guarter and year ended 31 March 2024. Pursuant to all necessary approvals and on finalisation of settlement agreements, the crystallized liability will be accounted after adjusting the provisions in this respect. Exceptional item in the Consolidated result for the quarter and full year ended 31 March 2024 includes Rs. 3,108.41 million and Rs 6,884.30 million respectively comprises of the U.S. Department of Justice, Antitrust

Division (DOJ) settlement ,related cost and remediation cost of manufacturing sites in USA. The Board of Directors of Glenmark Pharmaceuticals Inc., USA in their meeting held on 23 May, 2024 decided to impaired the block of OSD & Nebulizer within the manufacturing facility located in Monroe.

The decision was taken considering the high cost of production amidst pricing pressure & competition in the US market.

The focus, going forward, will be only on injectables where complex generic products would be commercialized, mainly for US market. In accordance with the provisions of IND AS 10 Events Occurring After Reporting Period, a total charge of Rs. 21,789.85 Mn (\$ 263.2 million) has been accrued as of 31 March, 2024 (including working capital adjustments). Exceptional Item also includes de-prioritisation of certain intangibles of Glenmark Speciality SA aggregating to Rs 11,000.77 Mn (\$133 million) and the consequent effect under the Accounting Standard IND AS 36

30.06.2023 Exceptional item of Rs.520,23 in the consolidated result for the quarter comprises of remediation cost of manufacturing sites in India and Monroe (USA).

6. On July 11 and 12, 2024, the Company sold its entire holding of 96,09,571 Equity Shares representing 7.84% of the total issued and paid-up equity share capital of the Glenmark Life Sciences Limited through the offer dated July 10, 2024 for sale through the stock exchange mechanism.

7. The figures for the quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended 31st December, 2023.

8. The list of subsidiaries as of 30 June, 2024 is provided in Annexure A.

Impairment of Intangible Assets.

Mumbai, 14 August 2024

Diluted EPS has been computed considering the effect of conversion of ESOPs. Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

financialexp.epapr.in

in Glenmark Lifescience Ltd, remediation, legal, inventory provision and others.

Glenmark Pharmaceuticals Limited

Annexure A List of entities included in the consolidated financial results for the quarter ended 30 June 2024

1. Glenmark Pharmaceuticals Europe Ltd., U.K. 2. Glenmark Pharmaceuticals S.R.O. 3. Glenmark Pharmaceuticals SK, S.R.O. 4. Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.A.) 5. Glenmark Holding S.A. 6. Glenmark Pharmaceuticals SP z.o.o. 7. Glenmark Pharmaceuticals Inc. 8. Glenmark Farmaceutical Ltda 10. Glenmark Generics S.A.11. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 12. Glenmark Pharmaceuticals Peru SAC 13. Glenmark Pharmaceuticals Colombia SAS. Colombia 14. Glenmark Pharmaceuticals Venezuela, C.A.16. Gle SRL 17, Glenmark Pharmaceuticals Egypt S.A.E. 18, Glenmark Pharmaceuticals FZE 19, Glenmark Pharmaceuticals (Nigeria) Ltd 22, Glenmark Pharmaceuticals Malaysia Sdn Bhd 23. Glenmark Pharmaceuticals (Australia) Pty Ltd 24. Glenmark South Africa (pty) Ltd 25. Glenmark Pharmaceuticals (On Ltd 27. Glenmark Pharmaceuticals (Australia) Pty Ltd 24. Glenmark Pharmaceuticals (On Ltd 27. Glen Glenmark Pharmaceuticals B.V. 28. Glenmark Arzneimittel GmbH - Germany 29. Glenmark Pharmaceuticals Canada Inc. 30. Glenmark Pharmaceuticals Kenya Ltd 31. Viso Farmaceutica S.L., Spain 32. Glenmark Specialty SA 33. Glenmark Pharmaceuticals Distribution s.r.o. 34. Glenmark Pharmaceuticals Nordic AB 35. Glenmark Ukraine LLC 36. Glenmark Pharmaceuticals Ecuador S.A. 37. Glenmark Pharmaceuticals Singapore Pte. Ltd. 38. Ichnos Sciences Biotherapeutics SA 39. Ichnos Sciences Inc., USA 40. Glenmark Life Sciences Limited (Upto 6th March 2024) 41. Glenmark Healthcare Limited (with effect from 12th May 2023) 42. Glenmark Farmaceutica SpA (with effect from 1st March 2023) 43. Sintesy Pharma S.R.L (with effect from 10st February 2023) 44. Glenmark Arzenimittel GmbH - Austria (with effect from 9st November 2023)

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

आरोपीला वाचवण्याचा प्रयत्न

राहुल गांधी यांचा कोलकात्यातील रुग्णालय प्रशासनावर आरोप

पीटीआय, नवी दिल्ली

कोलकाता येथे प्रशिक्षणार्थी डॉक्टरच्या बलात्कार आणि हत्येवरून ठिकठिकाणी आंदोलने सुरू आहेत. दरम्यान पीडितेला न्याय देण्याऐवजी रुग्णालय आणि स्थानिक प्रशासनाकडून आरोपीला वाचवण्याचा प्रयत्न सुरू असल्याचा गंभीर आरोप लोकसभेतील विरोधी पक्षनेते राहल गांधी यांनी बुधवारी केला. डॉक्टरच्या बलात्कार आणि हत्येच्या भीषण घटनेने संपूर्ण देश हादरला आहे. या अमानवी कत्याने डॉक्टर आणि महिलांमध्ये असुरक्षिततेचे असल्याचेही राहुल गांधी यांनी म्हटले आहे.

'पीडितेला न्याय देण्याऐवजी आरोपीला वाचवण्याचा प्रयत्न आणि स्थानिक प्रशासनाच्या भूमिकेवर गंभीर प्रश्न निर्माण करतो, असे राहुल यांनी 'एक्स'वरील संदेशात म्हटले. या घटनेने विचार करायला भाग पाडले आहे. वैद्यकीय महाविद्यालयासारख्या ठिकाणी डॉक्टरच सुरक्षित नसतील तर पालक आपल्या मुलींना बाहेर शिक्षणासाठी कसे पाठवतील, निर्भया प्रकरणानंतर केलेले कठोर कायदेही असे गन्हे रोखण्यात यशस्वी का झाले नाहीत. असे प्रश्न राहल यांनी उपस्थित केले आहेत.

'हाथरस ते उन्नाव आणि कठुआ ते कोलकाताच्या घटनेवरून महिलांवरील अत्याचार सातत्याने वाढत असल्याचे समोर येते. अशा घटनांवर प्रत्येक राजकीय पक्ष,



आंदोलनाने आरोग्य सेवा वेटीस

- पश्चिम बंगालमधील कनिष्ठ डॉक्टरांनी बुधवारी सहाव्या दिवशी सरकारी वैद्यकीय महाविद्यालय आणि रुग्णालयात हत्येच्या निषेधार्थ काम बंद ठेवले. या सुरू असलेल्या आंदोलनाचा मोठा परिणाम आरोग्य सेवांवर झाला. परिणामी सर्व सरकारी रुग्णालयांच्या बाह्यरुग्ण विभागांमध्ये (ओपीडी) रूग्णांच्या लांबच लांब रांगा लागल्या होत्या
- आंदोलक कनिष्ठ डॉक्टरांनी दंडाधिकाऱ्यांमार्फत या प्रकरणाची चौकशीची आणि आंदोलक ज्युनियर डॉक्टरांतर्फे महिला डॉक्टरच्या हत्येची दंडाधिकारी चौकशी आणि आर.जी. कार वैद्यकीय महाविद्यालय आणि रुग्णालयातील वरिष्ठ अधिकाऱ्यांना काढून टाकण्याच्या मागणीसाठी तीव्र आंदोलन सुरू आहे.

समाजातील प्रत्येक घटकाला गंभीर चर्चा करून ठोस पावले उचलावी लागतील. पीडित कुटुंबीयांच्या वेदनांमध्ये मी पाठीशी उभा आहे. त्यांना कोणत्याही परिस्थितीत न्याय मिळाला पाहिजे आणि दोषींना अशी शिक्षा मिळावी की ते समाजात उदाहरण म्हणन काम करेल.' असेही राहुल यांनी 'एक्स'वर म्हटले आहे. तत्पूर्वी या हत्येचा तपास कोलकाता पोलिसांकड्न केंद्रीय अन्वेषण ब्युरोकडे (सीबीआय) हस्तांतरित करण्याचे आदेश कोलकाता उच्च न्यायालयाने मंगळवारी दिले आहेत.

आसाममधील 'तो' निर्णय मागे गवाहाटी: आसाममधील सिलचर रुग्णालयाने बुधवारी महिला डॉक्टर आणि इतर कर्मचाऱ्यांना रात्रीच्या वेळी एकट्याने जाणे टाळण्यास सांगणारा निर्णय मागे घेतला आहे. कोलकाता येथील घटनेच्या पार्श्वभमीवर रुग्णालयाचे प्राचार्य आणि मुख्य अधीक्षक डॉ. भास्कर गुप्ता यांनी हा निर्णय जारी केला होता. आधी जाहीर केलेला निर्णय रद्द केला असन, या संदर्भात लवकरच नवीन निर्णय जाहीर केला जाईल. असे डॉ. गुप्ता यांनी सांगितले.



दिल्लीच्या इंदिरा गांधी आंतरराष्ट्रीय विमानतळावरील नवीन टर्मिनल-१ येत्या १७ ऑगस्टपासून सेवेत येणार आहे. २८ जून रोजी छत दुर्घटनेमुळे जुने टर्मिनल-१ तात्पुरते बंद करण्यात आले होते. येथील विमानवाहतूक टर्मिनल २ आणि ३ वर वळवण्यात आली होती. अत्याधुनिक टर्मिनल-१ ची प्रवासी क्षमता लक्षणीयरीत्या वाढण्यात आली आहे. प्रवाशांना येथे अत्याधुनिक सुविधा मिळणार आहेत.

हॅरिस यांचा जाहिरातींवर जोर

वॉशिंग्टन : अमेरिकेच्या राष्ट्राध्यक्षपदाच्या उमेदवार कमला



दशलक्ष डॉलर खर्च केले जाणार आहेत. हॅरिस यांची लढत माजी राष्ट्राध्यक्ष आणि रिपब्लिकन पक्षाचे उमेदवार डोनाल्ड ट्रम्प यांच्याशी होत आहे.

अध्यक्षपदाची ही निवडणक नोव्हेंबरमध्ये होत आहे. मतदानाच्या दिवसापर्यंतच्या साधारण दोन-अडीच महिन्यांच्या कालावधीत मतदारांना संदेश पाठवण्यासाठी केलेली ही आतापर्यंतची सर्वात महागडी प्रचारमोहीम आहे. गेल्या महिन्यात जो बायडेन यांच्याऐवजी हॅरिस यांना उमेदवारी जारी झाल्यानंतर तत्काळ ५० दशलक्ष डॉलर्सच्या जाहिरातींची नोंदणी करण्यात आली होती.

केजरीवाल यांना अंतरिम जामीन देण्यास नकार

सीबीआयला उत्तर देण्याचेही आदेश

नवी दिल्ली : दिल्लीचे मुख्यमंत्री अरविंद केजरीवाल यांना अंतरिम जामीन देण्यास



न्यायालयाने बुधवारी नकार दिला. कथित अबकारी धोरण

घोटाळ्याप्रकरणी (मद्य घोटाळा) केंद्रीय गुन्हे अन्वेषण विभागाने हा भ्रष्टाचाराचा खटला दाखल केला आहे. या प्रकरणी केजरीवाल यांच्या अटकेला आव्हान देणाऱ्या याचिकेवर न्यायालयाने तपास यंत्रणेकडन उत्तर मागितले आहे. या प्रकरणी पुढील सुनावणी ऑगस्ट रोजी होणार आहे.

न्या. सूर्यकांत आणि उज्जल भूयान यांच्या खंडपीठासमोर ही सुनावणी झाली. केजरीवाल यांच्या वतीने ज्येष्ठ वकील अभिषेक सिंघवी यांनी युक्तिवाद केला. आर्थिक गैरव्यवहार प्रकरणात केजरीवाल यांना तीन वेळा अंतरिम जामीन मिळाला होता. हे प्रकरण कथित मद्य घोटाळ्याशीही जोडले गेले होते. आर्थिक गैरव्यवहार प्रतिबंधक (पीएमएलए) कायद्यांतर्गत खटल्यांमध्ये जामीन मंजुर करण्यासाठी कठोर अटी असूनही जामीन मिळाला होता. भ्रष्टाचार प्रतिबंधक कायद्यात जामिनासाठी कठोर अटी नसल्याने त्यांना नियमित जामीन नाकारला जाऊ शकत नाही, असा युक्तिवाद सिंघवी यांनी केला. सर्वोच्च न्यायालयाने १० मे आणि १२ जुलै रोजी अंतरिम जामीन मंजुर केला होता, तर सत्र न्यायालयाने २० जन रोजी नियमित जामीन मंजुर केला होता, याकडे सिंघवी यांनी

न्यायालयाचे लक्ष वेधले.



S. No. 74/A, 74/B, Aranyeshwar Campus, Parvati, Pune - 411 009.

E-mail - ssmscoa@gmail.com | Website: www.ssmscoa.org Tel: 020 24222771, +91 7387916896

Approved by Council of Architecture, New Delhi, Govt. of Maharashtra & DTE (MS), **Affiliated to Savitribai Phule Pune University**

ADMISSION OPEN FOR B.ARCH & D.ARCH ACADEMIC YEAR 2024-25

DTE Institute Code: 6896

Application for admission to first year of 5 year full time Bachelor of Architecture (B.Arch) and 3 years Diploma in Architecture (D.Arch) are invited from eligible candidates for Institute seats and probable vacant seats after CAP round being cunducted by Competent Authority - Govt. of Maharashtra

First Year Degree & Diploma Architecture Course

Sr. No.	Courses Offered	Choice Code	INTAKE		
1	Bachelor of Architecture	689603210	40		
2	Diploma in Architecture	689680110	40		

Eliqibility: As per DTE (Maharashtra) Norms.

For Admission Enquiry Please Contact:

Admin Office - 7387916896 Mr. Atharva Mane - 9657738864 Ar. Sneha Dilwale - 9561311183 Ar. Shreyas Amraskar - 8698002236

Dr. Bajrang H. Sutar Principal Mob. No. 9822547748

Shri. Janardhan G. Thorat Hon. Secretary SHRI SHIVAJI MARATHA SOCIETY

वैद्यकीय आयोगाच्या (एनएमसी) निर्णयाला आव्हान देणारी याचिका सर्वोच्च न्यायालायने बुधवारी

नवी दिल्ली : नीट सुपर स्पेशालिटी

प्रवेश परीक्षा न घेण्याच्या राष्ट्रीय

'नीट'बाबतची आव्हान याचिका फेटाळली

चंद्रचुड आणि न्या. जे.बी. पारडीवाला आणि न्या. मनोज मिश्रा

यांच्या खंडपाठाने सनावणी घेतली. परीक्षेच्या वेळापत्रकाशी कोणतीही छेडछाड करण्यास न्यायालयाने

आयोगाचा निर्णय न्याय्य असल्याचे मत खंडपीठाने मांडले. राहल

बलवान यांच्यासह १३ डॉक्टरांनी ही याचिका दाखल केली होती. याप्रकरणी सर्वोच्च न्यायालयाने १९ जुलै रोजी राष्ट्रीय वैद्यकीय आयोगाला नोटीस बजावली होती.

glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026; Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099.

Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986; Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com; CIN: L24299MH1977PLC019982

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Sr. No.	Particulars	Standalone Quarter Quarter Year				Quarter	Quarter	lidated Quarter	Year	
110.		ended	ended	ended	ended	ended	ended	ended	ended	
		30/06/2024	31/03/2024	30/06/2023	31/03/2024	30/06/2024	31/03/2024	30/06/2023	31/03/2024	
_	Revenue from operations	(Unaudited)	(Refer note 7)	(Unaudited)	(Audited)	(Unaudited)	(Refer note 7)	(Unaudited)	(Audited)	
'	(a) Net sales	22,968.75	20,771.32	20,980.62	76,497.61	32,233.02	30,160.07	29,984.72	1,16,354.56	
	(b) Other operating income	326.62	710.91	463.22	2,413.58	208.84	469.45	375.94	1,776.4	
	Total revenue from operations	23,295.37	21,482.23	21,443.84	78,911.19	32,441.86	30,629.52	30,360.66	1,18,130.9	
=	Other income	556.48	7,862.70	493.61	11,680.24	314.92	7,731.65	197.22	8,399.9	
III IV	Total income (I + II)	23,851.85	29,344.93	21,937.45	90,591.43	32,756.78	38,361.17	30,557.88	1,26,530.9	
IV	Expenses (a) Cost of materials consumed	6,481.09	6,854.51	7,967.56	29,904.11	6.857.74	7,543.09	8.302.54	31,578.2	
	(b) Purchases of stock-in-trade	889.85	816.58	821.71	3,227.82	3,600.26	2,108.04	4,184.25	14,511.7	
	(c) Changes in inventories of finished goods, work-in-progress	569.24	(21.20)	(230.84)	(1,030.70)	642.82	304.15	(608.82)	(1,956.22	
	and stock-in-trade									
	(d) Employee benefits expense	3,844.03	3,377.45	3,344.66	14,347.75	7,104.40	7,009.55	6,812.73	28,681.4	
	(e) Finance costs (f) Depreciation, amortisation and impairment expense	153.49 530.87	833.85 524.01	619.34 487.52	2,771.10 2,021.62	395.82 1,177.89	1,485.59 1,513.37	1,116.08 1,420.40	5,159.6 5,819.0	
	(g) Other expenses	5,200.14	5,480.41	4,690.79	20,045.58	8,354.51	8,621.26	7,296.44	33,362.5	
	Total expenses (IV)	17,668.71	17,865.61	17,700.74	71,287.28	28,133.44	28,585.05	28,523.62	1,17,156.4	
٧	Profit/(loss) before exceptional items and tax (III - IV)	6,183.14	11,479.32	4,236.71	19,304.15	4,623.34	9,776.12	2,034.26	9,374.5	
VI	Exceptional items (gain)/ loss (Refer note 5)	-	(51,469.13)	316.29	(50,703.31)	-	4,467.85	520.23	9,009.5	
VII	Profit/(loss) before tax from continuing operations	6,183.14	62,948.45	3,920.42	70,007.46	4,623.34	5,308.28	1,514.03	364.9	
VIII	(V - VI) Tax expense :									
V 111	Current tax	1,079.84	10,553.79	385.65	10,499.92	1,468.82	10,581.74	567.23	11,155.5	
	Deferred tax	565.99	6,257.71	818.21	7,834.63	(247.86)	7,112.99	570.02	7,517.9	
IX	Profit/(loss) after tax for the period from continuing operations	4,537.31	46,136.95	2,716.56	51,672.91	3,402.38	(12,386.45)	376.78	(18,308.50	
	(VII - VIII)									
Χ	Profit/(loss) for the period from continuing operations attributable to:					(0.20)	40.10	224.04	604.4	
	Non-controlling interestsOwners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	(0.29) 3,402.67	40.10 (12,426.55)	231.94 144.84	681.4 (18,989.96)	
ΧI	Profit/(loss) before tax from discontinued operations	4,557.51	40,130.33	2,710.50	31,072.31	3,402.07	310.80	1,820.04	5,326.9	
XII	Tax expense of discontinued operations :							.,	0,020.0	
	Current tax					-	72.73	435.99	1,284.3	
	Deferred tax					-	(5.69)	29.55	69.3	
XIII	Profit/(loss) after tax for the period from discontinued operations					-	243.76	1,354.50	3,973.2	
XIV	(XI - XII) Profit/(loss) for the period from discontinued operations attributable to:									
ΛIV	- Non-controlling interests					_	_	-		
	- Owners of the Company					-	243.76	1,354.50	3,973.2	
XV	Profit/(loss) after tax for the period from continuing and discontinued					3,402.38	(12,142.69)	1,731.28	(14,335.22	
	operations (IX + XIII)									
XVI	Profit/(loss) for the period from continuing and discontinued									
	operations attributable to: - Non-controlling interests	_	_		_	(0.29)	40.10	231.94	681.4	
	- Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	(12,182.79)	1,499.34	(15,016.68	
XVII	Other comprehensive income from continuing operations		,	,	,	,	, , ,	,	,	
	A (i) Items that will not be reclassified to profit or loss	(12.52)	(9.74)	(7.50)	(73.14)	(7.01)	(94.10)	(5.52)	(163.06	
	(ii) Income tax relating to items that will not be reclassified to	4.37	9.44	2.23	25.56	2.79	26.65	2.23	42.7	
	profit or loss B (i) Items that will be reclassified to profit or loss	_	_	_	_	60.50	846.57	(564.37)	(399.03	
	(ii) Income tax relating to items that will be reclassified to profit	_	_	-	-	(1.36)	(20.13)	6.80	(79.97	
	or loss					()	(==::=)	5.55	(, -,-,	
XVIII	Total comprehensive income from continuing operations for the	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,627.47)	(184.08)	(18,907.81	
VIV	period/ year						(0.10)	(0.72)	(EC 00	
XIX	Other comprehensive income from discontinued operations for the period/ year					-	(0.19)	(0.73)	(56.23	
XX	Total comprehensive income from discontinued operations for the					_	243.57	1,353.77	3,917.0	
	period/ year (XIII + XIX)							.,	-,	
XXI	Other comprehensive income for the period/ year from continuing	(8.15)	(0.30)	(5.27)	(47.58)	54.92	758.79	(561.59)	(655.53	
VAZII	and discontinued operation (XVII + XIX)	4 500 40	40 400 05	0.744.00	F4 00F 00	0.457.00	(44 000 00)	4 400 00	(4.4.000.70	
XXII	Total comprehensive income for the period/ year from continuing and discontinued operation (XVIII + XX)	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,383.89)	1,169.69	(14,990.76	
XXIII	Total comprehensive income attributable to:									
	- Non-controlling interests	-	-	-	-	(0.26)	40.22	231.98	672.0	
	- Owners of the Company	4,529.16	46,136.65	2,711.29	51,625.33	3,457.56	(11,424.11)	937.71	(15,662.76	
XXIV	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.1	
XXV	Other equity (other than revaluation reserve)				2,29,424.01				78,197.0	
XXVI	Earning per share for continuing operations (EPS) (not annualised except for the year ended 31 March)									
	Basic (in Rupees)					12.06	(44.04)	0.51	(67.30	
	Diluted (in Rupees)					12.06	(44.04)	0.51	(67.30	
(XVII	Earning per share for discontinued operations (EPS)						(,)		(300	
	(not annualised except for the year ended 31 March)									
	Basic (in Rupees)					-	0.86	4.80	14.0	
^^ /!!!	Diluted (in Rupees)					-	0.86	4.80	14.0	
XXVIII	Earning per share for continuing and discontinued operations (EPS) (not annualised except for the year ended 31 March)									
	(not annualised except for the year ended 31 March) Basic (in Rupees)	16.08	163.50	9.63	183.13	12.06	(43.17)	5.31	(53.22	
	Diluted (in Rupees)	16.08	163.50	9.63	183.12	12.06	(43.17)	5.31	(53.22	

Diluted (in Rupees)

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The above results were reviewed by the Audit Committee at its meeting held on 13th August, 2024 and approved by the Board of Directors at their meetings held on 14th August, 2024. The results for the quarter ended 30" June, 2024 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- 4. As at 30th June, 2024, pursuant to Employee Stock Options Scheme 2016, 37,779 options were outstanding, which upon exercise are convertible into equivalent number of equity shares
- Exceptional items: Standalone:

Exceptional item in the standalone result for the quarter and year ended 31 March 2024 Rs. 51,469.13 million (gain) and Rs 50,703.31 million (gain) respectively, primarily comprises of stake sale (net of expenses) in Glenmark Lifescience Ltd, remediation, legal, inventory provision and others.

Pursuant to Board approval dated 21 September 2023, the Company entered into share purchase agreement with Nirma Limited (the "Buyer") for the sale of 91.895.379 equity shares representing 75.00% of the current issued and paidup equity share capital of Glenmark Life Sciences Limited ("GLS"), a subsidiary of the Company, to the Buyer at a price of INR 615/- per share, aggregating to INR 56,515 million (subject to adjustments as agreed among the parties), in accordance with the terms of the share purchase agreement dated 21 September 2023 among the Company, GLS and the Buyer. Accordingly, 91,895,379 equity shares representing 75% of the current issued and paid-up equity share capital of the GLS, were transferred by the Company to Buyer as follows:

A. On 6 March , 2024, 6,73,89,944 equity shares, representing 55% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer.

B. On 12 March , 2024, 2,45,05,435 equity shares, representing 20% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer. As required by Ind-AS 105 "Asset Held for Sale and Discontinued Operations," GLS had been classified as discontinued operations after eliminating intercompany transactions and relevant disclosures made in the

30.06.2023

Exceptional item of Rs.316.29 in the standalone result for the quarter comprises of remediation cost of manufacturing sites in India. Consolidated:

31.03.2024

Exceptional item in the Consolidated result for the quarter and full year ended 31 March 2024 is Rs. 4.467.85 million (loss) and Rs 9.009.55 million (loss) respectively primarily comprises of stake sale (net of expenses) in Glenmark Lifescience Ltd, impairment of certain block at Monroe facility, De-prioritisation of certain intangibles, settlement & legal cost, remediation cost and working capital adjustment

The US subsidiary Glenmark Pharmaceuticals Inc., USA ('Company') has entered into an agreement with the U.S. Department of Justice, Antitrust Division (DOJ) on 22 August, 2023 to resolve all of its court proceedings with the DOJ involving historical pricing practices relating to the generic drug pravastatin between 2013 and 2015. The Company has entered into a three-year Deferred Prosecution Agreement, and if the Company adheres to the terms of the agreement, including the payment of \$30 million, payable in six instalments, the DOJ will dismiss the pending Superseding Indictment.

The US subsidiary Glenmark Pharmaceuticals Inc., USA ('Company') is likely to enter into an agreement with the U.S. Department of Justice, Antitrust Civil Division (DOJ), subject to all necessary approvals being in place, to the extent of \$30 million (including related cost), to resolve all of its Civil court proceedings with the DOJ. Due to the non-recurring nature of the provision, the Company has classified this provision as an

exceptional item in the financial statements for the quarter and year ended 31 March 2024. Pursuant to all necessary approvals and on finalisation of settlement agreements, the crystallized liability will be accounted after adjusting the provisions in this respect. Exceptional item in the Consolidated result for the guarter and full year ended 31 March 2024 includes Rs. 3.108.41 million and Rs 6.884.30 million respectively comprises of the U.S. Department of Justice, Antitrust Division (DOJ) settlement ,related cost and remediation cost of manufacturing sites in USA.

The Board of Directors of Glenmark Pharmaceuticals Inc., USA in their meeting held on 23 May, 2024 decided to impaired the block of OSD & Nebulizer within the manufacturing facility located in Monroe.

The decision was taken considering the high cost of production amidst pricing pressure & competition in the US market.

The focus, going forward, will be only on injectables where complex generic products would be commercialized, mainly for US market.

In accordance with the provisions of IND AS 10 Events Occurring After Reporting Period, a total charge of Rs. 21,789.85 Mn (\$263.2 million) has been accrued as of 31 March, 2024 (including working capital adjustments) Exceptional Item also includes de-prioritisation of certain intangibles of Glenmark Speciality SA aggregating to Rs 11,000.77 Mn (\$133 million) and the consequent effect under the Accounting Standard IND AS 36 Impairment of Intangible Assets

30.06.2023 Exceptional item of Rs.520.23 in the consolidated result for the guarter comprises of remediation cost of manufacturing sites in India and Monroe (USA)

6. On July 11 and 12, 2024, the Company sold its entire holding of 96,09,571 Equity Shares representing 7.84% of the total issued and paid-up equity share capital of the Glenmark Life Sciences Limited through the offer dated July 10, 2024 for sale through the stock exchange mechanism

The figures for the quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended

31st December, 2023. 8. The list of subsidiaries as of 30 June, 2024 is provided in Annexure A

9. Diluted EPS has been computed considering the effect of conversion of ESOPs.

10. Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited

Mumbai, 14 August 2024

Annexure A List of entities included in the consolidated financial results for the quarter ended 30 June 2024

1. Glenmark Pharmaceuticals Europe Ltd., U.K. 2. Glenmark Pharmaceuticals S.R.O. 3. Glenmark Pharmaceuticals SK, S.R.O. 4. Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 5. Glenmark Holding S.A. 6. Glenmark Pharmaceuticals SP z.o.o. 7. Glenmark Pharmaceuticals Inc. 8. Glenmark Therapeutics Inc. 9. Glenmark Farmaceutica Ltda 10. Glenmark Generics S.A. 11. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 12. Glenmark Pharmaceuticals Peru SAC 13. Glenmark Pharmaceuticals Colombia SAS, Colombia 14. Glenmark Uruguay S.A. 15. Glenmark Pharmaceuticals Venezuela, C.A. 16. Glenmark Dominicana SRL 17. Glenmark Pharmaceuticals Egypt S.A.E. 18. Glenmark Pharmaceuticals FZE 19. Glenmark Impex L.L.C 20. Glenmark Philippines Inc. 21. Glenmark Pharmaceuticals (Nigeria) Ltd 22. Glenmark Pharmaceuticals Malaysia Sdn Bhd 23. Glenmark Pharmaceuticals (Australia) Pty Ltd 24. Glenmark South Africa (pty) Ltd 25. Glenmark Pharmaceuticals South Africa (pty) Ltd 26. Glenmark Pharmaceuticals (Thailand) Co. Ltd 27. Glenmark Pharmaceuticals B.V. 28. Glenmark Arzneimittel GmbH - Germany 29. Glenmark Pharmaceuticals Canada Inc. 30. Glenmark Pharmaceuticals Kenya Ltd 31. Viso Farmaceuticals S.L., Spain 32. Glenmark Specialty SA 33. Glenmark Pharmaceuticals Distribution s.r.o. 34. Glenmark Pharmaceuticals Nordic AB 35. Glenmark Ukraine LLC 36. Glenmark-Pharmaceuticals Ecuador S.A. 37. Glenmark Pharmaceuticals Singapore Fermaceutica SpA (with effect from 1st March 2023) 43. Sintesy Pharma S.R.L (with effect from 10th February 2023) 44. Glenmark Arzenimittel GmbH - Austria (with effect from 9th November 2023)

> For and on behalf of the Board of Directors Glenn Saldanha

Chairman & Managing Director